Skip to main content
Almirall S.A. logo

Almirall S.A. — Investor Relations & Filings

Ticker · ALM ISIN · ES0157097017 LEI · 95980020140005007996 MC Manufacturing
Open in API
Filings indexed 284 across all filing types
Latest filing 2023-01-04 Transaction in Own Shar…
Country ES Spain
Listing MC ALM

About Almirall S.A.

http://www.almirall.com

Almirall S.A. is a global biopharmaceutical company specializing in medical dermatology. The company focuses on the research, development, manufacturing, and commercialization of proprietary medicines to address significant unmet needs in skin health. Leveraging scientific innovation, Almirall provides medical solutions designed to improve the well-being and quality of life for patients. Its operations encompass in-house research and development, strategic partnerships, and in-licensing to expand its portfolio of dermatological treatments.

Recent filings

Filing Released Lang Actions
Operaciones del contrato de liquidez durante el cuarto trimestre de 2022
Transaction in Own Shares Classification · 98% confidence The document is titled "OTRA INFORMACIÓN RELEVANTE" (Other Relevant Information) and explicitly states it is reporting on operations conducted under a liquidity contract ('contrato de liquidez') for the period from October 1, 2022, to December 31, 2022. It details the number of shares bought ('Compras') and sold ('Ventas') during this period, along with associated cash flows. This type of disclosure, reporting on transactions in the company's own shares (repurchases or sales) under a specific program, directly corresponds to the definition of 'Transaction in Own Shares' (POS). Although the document details transactions, it is a formal regulatory disclosure (Hecho Relevante) reporting these specific activities, not a general announcement about publishing a report (RPA) or a comprehensive financial statement (10-K/IR). The core subject is the company's own share activity.
2023-01-04 Spanish
Almirall licencia a perpetuidad Motilex® a Teofarma en Italia
Regulatory Filings Classification · 95% confidence The document is very short (671 characters) and announces a specific business event: Almirall licensing the drug Motilex® to Teofarma in Italy. It is framed as 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) and mentions compliance with securities law ('Ley del Mercado de Valores'). This type of specific, material business update that doesn't fit neatly into standard financial reports (like 10-K, ER, IR) or specific corporate actions (like DIV, CAP, M&A) is best classified as a general Regulatory Filing or announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a specific, material, non-standard announcement, although it could also be considered a general business update. Since it is a direct announcement of a licensing deal, which is a significant corporate event, and it doesn't match any other specific code (like TAR for M&A), RNS is the best fit as a general regulatory disclosure.
2022-11-18 Spanish
Almirall realizará una presentación vía webcast para explicar los Resultados del tercer trimestre de 2022
Report Publication Announcement Classification · 95% confidence The document is a short announcement dated November 10, 2022, stating that Almirall will hold a webcast to present and comment on the Third Quarter 2022 results on the same day. It explicitly mentions that the event can be followed live and the recording will be available on the website. Crucially, it states, "Adjuntamos el Calendario Financiero 2023" (We attach the Financial Calendar 2023) and provides the calendar. Since the document itself is an announcement about an upcoming presentation/webcast of results and includes a future financial calendar, but is not the full results document (ER or IR), it fits the description of announcing the publication or availability of financial information/events. Given the short length and the focus on announcing the presentation of results and attaching a calendar, the most appropriate classification is Report Publication Announcement (RPA), as it announces the release/availability of information related to financial results.
2022-11-10 Spanish
Carlos Gallardo, actual Presidente, es nombrado Consejero Delegado interino
Board/Management Information Classification · 98% confidence The document text is very short (672 characters) and announces a significant change in senior management: the current Chairman, Carlos Gallardo, is appointed as the Interim CEO following the departure of the previous CEO, Gianfranco Nazzi. This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in senior management.
2022-11-03 Spanish
Almirall anuncia la aceptación por parte de la EMA de la solicitud de autorización de comercialización (MAA) de lebrikizumab para la dermatitis atópica
Regulatory Filings Classification · 100% confidence The document is a formal announcement dated November 28, 2022, from Almirall, S.A., stating that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for lebrikizumab for atopic dermatitis. It cites compliance with the Securities Market Law ("Ley del Mercado de Valores") and provides details about clinical trial results (ADvocate 1, 2, ADhere). This type of announcement, detailing significant regulatory or clinical milestones that impact the company's operations or future revenue, is typically classified as 'Other Information Relevant' or a general regulatory disclosure. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific transaction (CAP, TAR), it fits best under the general regulatory announcement category, which is RNS (Regulatory Filings), as it is a mandatory disclosure of material information to the market.
2022-10-28 Spanish
Operaciones del contrato de liquidez durante el tercer trimestre de 2022
Transaction in Own Shares Classification · 99% confidence The document is a formal communication from Almirall, S.A. dated October 4, 2022, addressed to the CNMV (Comisión Nacional del Mercado de Valores - the Spanish securities market regulator). The content explicitly details the operations (purchases and sales of shares) conducted under a standing liquidity contract (share buyback/stabilization agreement) for the third quarter of 2022 (July 1 to September 30, 2022). This activity—the company transacting in its own shares—is specifically classified as a 'Transaction in Own Shares' (POS). The document provides the summary table and the detailed daily transaction log, confirming it is a report of this activity, not just an announcement of a report.
2022-10-04 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.